A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Trial Profile

A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Lenzilumab (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Proof of concept; Therapeutic Use
  • Sponsors Humanigen; KaloBios Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
    • 29 Jan 2014 Top-line results published in a KaloBios media release.
    • 29 Jan 2014 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met according to top-line results published in a KaloBios media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top